Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$94 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
--
EV/EBITDA
-1.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.3
Face value
--
Shares outstanding
30,487,700
CFO
$-188.73 Mln
EBITDA
$-295.23 Mln
Net Profit
$416.28 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
XBiotech (XBIT)
| -24.8 | 1.0 | -4.5 | -64.8 | -19.6 | -24.1 | -15.4 |
|
BSE Sensex*
| 4.4 | 4.0 | 7.8 | 10.3 | 14.5 | 21.5 | 11.4 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
XBiotech (XBIT)
| 14.0 | -68.5 | -28.9 | -16.2 | 267.4 | 28.8 | -61.1 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The... company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Address: 5217 Winnebago Lane, Austin, TX, United States, 78744 Read more
Founder, President, CEO & Chairman
Mr. John Simard
Founder, President, CEO & Chairman
Mr. John Simard
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of XBiotech Inc (XBIT) stood at $ 340 Mln as on 31-Mar-25
The share price of XBiotech Inc (XBIT) is $2.97 (NASDAQ) as of 20-May-2025 16:02 EDT. XBiotech Inc (XBIT) has given a return of -19.63% in the last 3 years.
XBiotech Inc (XBIT) has a market capitalisation of $ 94 Mln as on 20-May-2025. As per Value Research classification, it is a company.
The P/B ratio of XBiotech Inc (XBIT) is 0.54 times as on 20-May-2025, a 83% discount to its peers’ median range of 3.16 times.
Since, TTM earnings of XBiotech Inc (XBIT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the XBiotech Inc (XBIT) and enter the required number of quantities and click on buy to purchase the shares of XBiotech Inc (XBIT).
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Address: 5217 Winnebago Lane, Austin, TX, United States, 78744
The CEO & director of Mr. John Simard. is XBiotech Inc (XBIT), and CFO & Sr. VP is Mr. John Simard.
There is no promoter pledging in XBiotech Inc (XBIT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| XBiotech Inc. (XBIT) | Ratios |
|---|---|
|
Return on equity(%)
|
-21.49
|
|
Operating margin(%)
|
-4666.55
|
|
Net Margin(%)
|
-4545.91
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of XBiotech Inc (XBIT) was $0 Mln.
$-0.10
(
